文献速递心力衰竭与心肌病心律失常血脂与心血管预防

非缺血性心肌病的一级预防ICD与心脏性猝死风险评估机遇

Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
PubMed 文献 · Eur Heart J · 2018-01-01

非缺血性心肌病(NICM)患者中,心脏性猝死(SCD)约占全部死亡的三分之一。预防性ICD植入在单个NICM试验中未显示 mortality benefit,但汇总分析(含DANISH试验)显示全因死亡率显著降低,且各试验一致显示SCD风险降低。本综述讨论ICD试验演变,并强调有前景的猝死风险分层标志物。

要点

  • NICM患者SCD约占全部死亡三分之一,预防性ICD是高风险患者的主要干预。
  • 单个NICM ICD试验未显示预防性ICD的死亡率获益,但汇总分析显示全因死亡率显著降低。
  • 各NICM ICD试验一致显示ICD较单纯药物治疗降低SCD风险,精细风险分层可能提高ICD疗效。

核心结论

  • 在NICM人群中,预防性ICD植入在单个试验中未显示死亡率获益,但汇总分析显示全因死亡率显著降低且SCD风险一致降低。
  • 采用精细风险分层筛选SCD最高危患者可能显著提高ICD疗效。

研究设计与样本

  • 本文为临床综述,讨论评估NICM人群ICD的临床试验演变,并重点介绍有前景的SCD风险分层标志物。

主要发现

  • NICM患者中SCD约占全部死亡的三分之一。
  • 单个NICM人群ICD试验未能证明预防性ICD植入的死亡率获益。
  • 汇总分析(涵盖三十年多项试验并包括DANISH试验)报告ICD植入较单纯药物治疗显著降低全因死亡率。
  • 每项试验均一致显示ICD较单纯药物治疗降低SCD风险。

关键数值与推荐

  • 现行指南推荐对有症状心力衰竭且左心室射血分数≤35%的NICM患者植入ICD。
  • 指南推荐基于多项试验的荟萃分析,这些试验跨越三十年并包括DANISH试验。

临床怎么用

  • 对NICM合并有症状心衰且LVEF≤35%的患者,按指南评估ICD植入指征。
  • 在ICD决策中可关注SCD风险分层标志物,以个体化筛选最高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sudden cardiac death (SCD) accounts for approximately one-third of all deaths among patients with non-ischaemic cardiomyopathy (NICM). Implantable cardioverter-defibrillator (ICD) therapy has been the primary intervention for managing individuals at high risk for SCD. However, individual ICD trials in the NICM population have failed to demonstrate a mortality benefit with prophylactic ICD implantation. Current guidelines recommend ICD implantation in NICM patients with symptomatic heart failure and a left ventricular ≤35% and are based on meta-analyses of multiple trials that span three decades and include the recent Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischaemic Heart Failure on Mortality (DANISH) trial. These pooled analyses report a significant reduction in all-cause mortality with ICD implantation compared with medical therapy alone. In addition, each of these trials has demonstrated consistently a reduction in the risk of SCD compared with medical therapy alone. As a result, a refined approach of risk stratification that selects patients at the highest risk for SCD may lead to a significant improvement in ICD efficacy. In this clinical review, we first discuss the evolution of clinical trials that have evaluated ICDs in the NICM population. We then highlight some key markers of arrhythmia risk that hold promise in personalizing risk stratification for SCD.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Pathak RK, Sanders P, Deo R, et al. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy. Eur Heart J. 2018. PMID: 30020440. doi:10.1093/eurheartj/ehy344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。